Virtual Acquisition
Executive Summary
In a partnering-crazy industry, when alliances are at record levels, it's easy to lose sight of the fact that alliances can often be acquisitions in disguise, once everything of value has been licensed off. With its latest deal with Procter & Gamble, which followed earlier deals with Amgen, Glaxo Wellcome, Medtronic, and Sumitomo, Regenergon Pharmaceuticals may be partnered out.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.